Literature DB >> 19900228

Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with Type 2 diabetes.

R Peter1, G Dunseath, S D Luzio, R Chudleigh, S R Choudhury, D R Owens.   

Abstract

AIMS: To determine the relative and absolute contributions of postprandial glucose (PPG) and fasting or preprandial plasma glucose (FPG) to daytime hyperglycaemia and HbA(1c) respectively, in persons with type 2 diabetes (T2DM).
METHODS: Subjects (n = 52; 37 men) had 12hr plasma glucose (PG) profiles determined in response to three serial identical test meals. PPG exposure was calculated for each meal. Excess hyperglycaemia was calculated above a PG concentration of 5.5 mmol/l. Fasting hyperglycaemia was the difference between excess hyperglycaemia and PPG exposure. Subjects were divided into three groups according to HbA(1c)-(Gp1:<7.3%;Gp2:7.3%-8.0%;Gp3:>8.0%) and the relative contribution of PPG exposure and fasting hyperglycaemia to excess hyperglycaemia calculated for each meal. The absolute contribution of PPG and fasting hyperglycaemia to excess HbA(1c) (mean HbA(1c)-5.1%) was also calculated.
RESULTS: The relative contributions of PPG exposure to excess hyperglycaemia for the three groups were: 58.3%, 54.3% and 35.4% (P = 0.483-Group 1 vs. Group 2; P = 0.002-Group 2 vs. Group 3) for meal 1; 69.8%, 54.7% and 23.7% (P = 0.163-Group 1 vs. Group 2; P = 0.005-Group 2 vs. Group 3) for meal 2; 85.8%, 70.2% and 48.6% (P = 0.153-Group 1 vs. Group 2; P = 0.046-Group 2 vs. Group 3) for meal 3. Absolute contributions of PPG to excess HbA(1c) in the three groups were 1.4%, 1.6% and 1.3% (P = NS).
CONCLUSION: The relative contribution of postprandial glucose to excess hyperglycaemia decreases as glycaemic control deteriorates, being dominant with HbA(1c)</= 7.3%, irrespective of the timing of the meal during the day. However, the absolute contribution of postprandial glucose to excess HbA(1c) does not differ significantly ( approximately 1.5%) with varying glycaemic control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900228     DOI: 10.1111/j.1464-5491.2009.02809.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  15 in total

Review 1.  Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.

Authors:  L Monnier; C Colette; S Dejager; D R Owens
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

2.  Contributions of Basal Glucose and Postprandial Glucose Concentrations to Hemoglobin A1c in the Newly Diagnosed Patients with Type 2 Diabetes--the Preliminary Study.

Authors:  Xin Kang; Chun Wang; Dawei Chen; Lifang Lv; Guanjian Liu; Jie Xiao; Yanzhi Yang; Liping He; Lihong Chen; Xiujun Li; Haoming Tian; Weiping Jia; Xingwu Ran
Journal:  Diabetes Technol Ther       Date:  2015-03-31       Impact factor: 6.118

Review 3.  Combining basal insulin analogs with glucagon-like peptide-1 mimetics.

Authors:  Riccardo Perfetti
Journal:  Diabetes Technol Ther       Date:  2011-06-28       Impact factor: 6.118

4.  Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.

Authors:  Frances Stringer; Joost DeJongh; Kazuaki Enya; Emiko Koumura; Meindert Danhof; Kohei Kaku
Journal:  Diabetes Technol Ther       Date:  2014-12-22       Impact factor: 6.118

5.  t-Resveratrol Protects against Acute High Glucose Damage in Endothelial Cells.

Authors:  Leda Guzmán; Cristóbal Balada; Guillermo Flores; Rocío Álvarez; Marcela Knox; Raúl Vinet; José L Martínez
Journal:  Plant Foods Hum Nutr       Date:  2018-09       Impact factor: 3.921

6.  An assessment of patient behavior over time-periods: a case study of managing type 2 diabetes through blood glucose readings and insulin doses.

Authors:  Josephine Namayanja; Vandana P Janeja
Journal:  J Med Syst       Date:  2012-10-27       Impact factor: 4.460

Review 7.  The glucose triad and its role in comprehensive glycaemic control: current status, future management.

Authors:  A Ceriello
Journal:  Int J Clin Pract       Date:  2010-09-23       Impact factor: 2.503

8.  Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes.

Authors:  Matthew Riddle; Guillermo Umpierrez; Andres DiGenio; Rong Zhou; Julio Rosenstock
Journal:  Diabetes Care       Date:  2011-10-25       Impact factor: 19.112

9.  Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

Authors:  Matthew C Riddle; Thomas Forst; Ronnie Aronson; Leobardo Sauque-Reyna; Elisabeth Souhami; Louise Silvestre; Lin Ping; Julio Rosenstock
Journal:  Diabetes Care       Date:  2013-04-05       Impact factor: 19.112

10.  Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.

Authors:  C Kapitza; T Forst; H-V Coester; F Poitiers; P Ruus; A Hincelin-Méry
Journal:  Diabetes Obes Metab       Date:  2013-02-25       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.